GLP-1s & Weight Loss

Retatrutide

Educational research reference. This page was restored from the structured compound dataset included with this site export. Protocol examples are context for review and are not medical advice.

At a glance

Route(s)

Subcutaneous

Target

GLP-1; GIP; Glucagon

Timing window

Morning

Regulatory status

investigational not fda approved

Protocol context

Standard Protocol

Timeframe	Dose / exposure	Notes
Weeks 1-4	2.0mg once weekly	Initiation phase.
Weeks 5-8	4.0mg once weekly	Therapeutic escalation.
Weeks 9-12	6.0mg once weekly	Monitor heart rate carefully at this stage.
Weeks 13-16	8.0mg once weekly	Advanced plateau breaker.
Weeks 17-20	10.0mg once weekly	Pre-maximum dose.
Weeks 21+	12.0mg once weekly	Maximum studied dose. Highly advanced subjects only.

Alternative: Conservative Start

Timeframe	Dose / exposure	Notes
Weeks 1-4	0.5mg to 1.0mg once weekly	Significantly lowers cardiovascular stress and initial heart rate spikes.
Weeks 5-8	2.0mg once weekly	Moves into standard initiation phase.
Weeks 9-12	3.0mg once weekly	Titrating by 1mg instead of 2mg prevents extreme hyperesthesia (skin sensitivity).
Weeks 13+	4.0mg once weekly	Continue titrating by 1.0mg as needed based on tolerance.

Protocol logic

Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; GIP; Glucagon); route Subcutaneous; timing Morning. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.

Side effects / cautions listed in dataset

Elevated resting heart rate (tachycardia): driven by glucagon receptor agonism; the most pharmacologically unique side effect of this compound vs. other incretins.
Skin hyperesthesia: unusual sensitivity or hypersensitivity to touch, particularly on the arms, torso, and thighs; dose-dependent and most prominent at higher doses.
Nausea: common during dose escalation phases.
Vomiting.
Diarrhea.
Constipation.
Abdominal pain and cramping.
Decreased appetite and dysgeusia (altered taste).
Gastroparesis: delayed gastric emptying; may persist even with pre-operative fasting.
Fatigue and lethargy: particularly pronounced during early high-dose phases.
Headache.
Dizziness.
Elevated blood pressure: secondary to heart rate increases and sympathomimetic effects of glucagon receptor activation.
Hypoglycemia: risk elevated when combined with insulin or sulfonylureas.
Acute pancreatitis: documented in incretin class compounds; causal relationship under investigation.
Acute kidney injury: primarily mediated by dehydration from GI side effects.
Cholelithiasis (gallstones): risk increases with rapid weight loss.
Thyroid C-cell tumor risk: confirmed in rodent models; human risk not yet established; monitor for neck mass, hoarseness, or dysphagia.
Alopecia (hair loss): reported across incretin class; likely secondary to rapid caloric restriction.
Injection site reactions: redness, itching, bruising at administration site.
Anaphylaxis and angioedema: rare but documented across the incretin class.
Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
Rapid weight regain upon discontinuation: expected without lifestyle intervention; metabolic rate normalization post-cessation accelerates rebound.

Contraindications / risk flags listed in dataset

Personal or family history of Medullary Thyroid Carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Personal or family history of thyroid C-cell tumors.
Pre-existing cardiac arrhythmias or tachycardia: glucagon receptor activation directly elevates heart rate.
Uncontrolled hypertension: cardiovascular stress from glucagon agonism may exacerbate elevated blood pressure.
History of acute pancreatitis.
Severe gastroparesis or clinically significant delayed gastric emptying.
Type 1 diabetes mellitus.
Diabetic ketoacidosis.
Pregnancy: insufficient safety data; discontinue well in advance of planned conception.
Breastfeeding: insufficient safety data.
Known hypersensitivity or anaphylaxis to retatrutide or any formulation excipient.
Concurrent use with any other GLP-1, GIP, or glucagon receptor agonist: direct pharmacological conflict and additive cardiovascular risk.
History of suicidal ideation or prior suicide attempts: monitor closely.
Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols.
Severe hepatic impairment: glucagon receptor activity directly affects hepatic metabolism; limited safety data.
End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.
Pediatric use: safety and efficacy not established.
Use in subjects with active cardiovascular disease without cardiac monitoring: resting heart rate elevations of 8-10 BPM or more have been reported in clinical trials.

Related compounds

Synergistic / related

AOD-9604 Tesofensine